— m8 Pharmaceuticals and Biocodex have signed an exclusive licensing agreement for the Mexican and Brazilian market for Diacomit® (stiripentol). Diacomit® is an antiepileptic drug approved for adjunctive treatment in Dravet syndrome also known as severe myoclonic epilepsy in infancy (SMEI). Dravet syndrome is a very severe and very rare disease that is thought to affect approximately 1,000 to 2,000 patients in Mexico, and approximately 2,000 to 4,000 patients in Brazil.
The addition of Diacomit® to the m8 portfolio further reinforces the company’s position as a Latin American leader in the CNS space.
“We remain committed to bringing products to Latin America. Actively partnering with neurologists to address the unmet needs of patients and their families, as is the case of this devastating orphan disease which mainly affects children…” said Joel Barlan, m8’s CEO.
“We are pleased to have entered into this collaboration with m8 which is a major step forward to Diacomit development in Latin America. With this partnership in Mexico and Brazil, we are aiming at providing access to Diacomit to a large number of patients suffering from this severe condition” adds Nicolas Coudurier, CEO of Biocodex.